Many combination therapy regimens have recently been developed to target high-risk leukemia, including the BCL2i/BETi (40), CDK7i/BETi (25), CBP/P300/BETi (48), and JMJD6i/BETi (49). The gene discussed is EP300; the disease is leukemia.